Long-Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis.

ABSTRACT:

Objective

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing, inflammatory disease. Management of EGPA predominantly relies on oral corticosteroids (OCS), which are associated with many adverse effects. The phase 3 MIRRA trial demonstrated efficacy and safety of mepolizumab, anti-interleukin-5 biologic, for EGPA. This open-label extension (OLE) of MIRRA assessed long-term safety and OCS-sparing effects of mepolizumab.

Methods

The OLE (NCT03298061) was a multicenter study that enrolled patients from MIRRA who required OCS ≥5 mg/day up to six months after the end of MIRRA. All patients received mepolizumab 300 mg subcutaneously every four weeks plus standard of care until mepolizumab was discontinued or became approved and reimbursed for EGPA in the resp

SUBMITTER: Wechsler ME 

PROVIDER: S-EPMC12295670 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature